1,623 results on '"DEL PRATO, Stefano"'
Search Results
152. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?
153. Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
154. 986-P: Evaluation of Cardiovascular Risk and All-Cause Mortality in Type 1 Diabetes: Comparison of Risk Engines in a 10-Year Follow-up
155. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
156. Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist ( GLP ‐1 RA ) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP ‐1 RA use at screening
157. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
158. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin: A preliminary echocardiographic study
159. 2009 SIPREC Consensus Document — Executive Summary: Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance
160. Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance
161. Blood Glucose Control and Coronary Heart Disease
162. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors’ Expert Forum
163. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
164. Prognostic implications of diabetes phenotyping: new concepts for an old disease
165. Unlocking the opportunity of tight glycaemic control: Far from goal
166. Optimizing management of metabolic syndrome to reduce risk: focus on life-style
167. β-cell failure in type 2 diabetes mellitus
168. Highlights from International Congress: The XI Forum on the Renin-Angiotensin System, Capri, Italy, 11–12 April, 2008
169. Insulin secretion and action affect glucose variability in the early stages of glucose intolerance.
170. Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care 2021;44:1062–1069
171. Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141
172. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis
173. Review for "Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE‐HF Trial"
174. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
175. High insulin levels impair intracellular receptor trafficking in human cultured myoblasts
176. Metabolic Syndrome: Diagnosis and Clinical Management, an Official Document of the Working Group of the Italian Society of Cardiovascular Prevention (SIPREC)
177. Coxsackie B4 virus infection of [beta] cells and natural killer cell insulitis in recent-onset type 1 diabetic patients
178. Review of methods for detecting glycemic disorders.
179. New-Onset Diabetes in Covid-19
180. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial
181. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors
182. When and how to restore β-cell function?
183. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes
184. Left Ventricular Function in Normotensive Young Adults With Well-Controlled Type 1 Diabetes Mellitus
185. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
186. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
187. Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs
188. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
189. Type 1 diabetes and COVID-19: The “lockdown effect”
190. 2. Pharmacological Treatment of Type 2 Diabetes: Advantages and Dilemmas
191. Insulin as an Early Treatment for Type 2 Diabetes: ORIGIN or end of an old question?
192. Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
193. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum
194. Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study
195. Chapter 3 Interpretation of recent clinical trials concerning tight glycaemic control and cardiovascular risk
196. Characterization of tirzepatide-treated patients achieving HbA1c <5.7% in the SURPASS 1-4 trials.
197. The density of crown-like structures in epicardial adipose tissue could play a role in cardiovascular diseases
198. The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
199. Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance
200. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.